Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 10, 2012
On February 9, 2012, the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one abstention that the data in the company's...
-
Jan 9, 2012
Exton, PA, January 9, 2012 -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox Chase") in Philadelphia, PA...
-
Jan 3, 2012
Woodcliff Lake, NJ, January 3, 2012 — Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding...
-
Dec 15, 2011
Tokyo, Japan, December 15, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Dec 2, 2011
Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based...